1-3 of 3
Yashma Patel
Close
Sort by
Journal Articles

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

Adam Ivey, Robert K Hills, Michael A Simpson, Jelena V Jovanovic, Amanda F Gilkes, MSc, Yashma Patel, Neesa Bhudia, Hassan Farah, Joanne Mason, Kerry Wall, Susanna Akiki, Ellen Solomon, Frank McCaughan, David C Linch, FMedSci, Rosemary E Gale, PhD, Paresh Vyas, Sylvie D Freeman, Nigel Russell, Alan K. Burnett, MDFRCP, David Grimwade
Journal: Blood
Blood (2014) 124 (21): 70.
https://doi.org/10.1182/blood.V124.21.70.70
Published: 2014
Journal Articles

The impact on outcome of the addition of all- trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1 , FLT3 , and CEBPA

Clinical Trials & Observations
Alan K. Burnett, Robert K. Hills, Claire Green, Sarah Jenkinson, Kenneth Koo, Yashma Patel, Carol Guy, Amanda Gilkes, Donald W. Milligan, Anthony H. Goldstone, Archibald G. Prentice, Keith Wheatley, David C. Linch, Rosemary E. Gale
Journal: Blood
Blood (2010) 115 (5): 948–956.
https://doi.org/10.1182/blood-2009-08-236588
Published: 2010
Includes: Supplemental data
Journal Articles

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Rosemary Gale, PhD, Robert Hills, MA, MSc, DPhil, Claire Green, Yashma Patel, Amanda Gilkes, Michelle Lazenby, Keith Wheatley, DPhil, David C. Linch, FRCP, Alan Burnett
Journal: Blood
Blood (2008) 112 (11): 554.
https://doi.org/10.1182/blood.V112.11.554.554
Published: 2008